Credit Suisse (SIX:CSGN) analyst Martin Auster maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) Corp. on Thursday, setting a price target of $145, which is approximately 22.50% above the present share price of $118.37.
Auster expects United Therapeutics Corp . to post earnings per share (EPS) of $3.14 for the third quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in United Therapeutics, with an average price target of $155.14.
The analysts price targets range from a high of $243 to a low of $125.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $356.3 million and a net profit of $166.7 million. The company's market cap is $5.33 billion.
According to TipRanks.com, Credit Suisse analyst Martin Auster is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.6% and a 58.56% success rate.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.